Combination of TRC105 and Avastin did not improve the median progression free survival versus single agent Avastin in recurrent glioblastoma patients Combination was associated with a non-significant increase in overall survival SAN DIEGO, Feb. 09, 2017 — TRACON Pharmaceuticals , a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, today reported top-line results from a randomized Phase 2 clinical trial of TRC105 in recurrent glioblastoma funded and conducted by the Clinical Therapy Evaluation Program of the National Cancer Institute .
Category: National Cancer Institute
Threshold Pharmaceuticals and National Cancer Institute to Collaborate on Drug Candidate TH-3424
Threshold Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company developing novel therapies for cancer, today announced that it has entered into a collaboration with the National Cancer Institute , part of the National Institutes of Health , to study TH-3424, the company’s new drug candidate for the treatment of cancer. The collaboration will explore the effects of TH-3424 against T-cell acute lymphoblastic leukemia xenograft cell lines with high AKR1C3 expression.